Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities
- 4 April 2003
- journal article
- occasional survey
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 30 (6), 917-920
- https://doi.org/10.1007/s00259-003-1142-0
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activitiesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003
- [177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- 90Y and 177Lu Labeling of a DOTA-Conjugated Vitronectin Receptor Antagonist Useful for Tumor TherapyBioconjugate Chemistry, 2001
- Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectivesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Peptide receptor imaging and therapy.2000
- Equilibria and formation kinetics of some cyclen derivative complexes of lanthanidesInorganica Chimica Acta, 2000
- The Role of Radioactive Somatostatin and Its Analogues in the Control of Tumor GrowthPublished by Springer Science and Business Media LLC ,2000
- G‐protein coupled receptor kinases as modulators of G‐protein signallingThe Journal of Physiology, 1999
- DOTATOC: A powerful new tool for receptor-mediated radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- The chemistry of gallium and indium as related to radiopharmaceutical productionInternational Journal of Nuclear Medicine and Biology, 1981